中国实用内科杂志2025，Vol.45Issue(6)：454-462,9.DOI:10.19538/j.nk2025060102
肺癌新辅助治疗的争议与共识
Controversies and consensuses on neoadjuvant therapy for lung cancer
摘要
Abstract
For patients with potentially resectable lung cancer,neoadjuvant therapy is crucial and plays a key role in improving the overall prognosis of those with locally advanced lung cancer.Neoadjuvant therapy for lung cancer includes neoadjuvant targeted therapy,neoadjuvant immunotherapy,and neoadjuvant chemoradiotherapy,which have demonstrated significant efficacy in shrinking tumor lesions and reducing tumor staging.This,in turn,provides more surgical options and helps reduce the risk of postoperative recurrence and distant metastasis.Multiple cohort studies have confirmed that,compared to surgery alone,neoadjuvant therapy can provide long-term therapeutic benefits.Currently,there is consensus on the population suitable for neoadjuvant therapy,but controversies remain regarding specific treatment approaches.With the continuous emergence of high-quality clinical trial results and the development of new technologies,it will be possible to establish larger-scale,geographically broader basic and clinical research initiatives,promoting advancements in personalized treatment strategies and ultimately benefiting patients.关键词
肺癌/新辅助治疗/靶向治疗/免疫治疗Key words
lung cancer/neoadjuvant therapy/targeted therapy/immunotherapy分类
临床医学引用本文复制引用
金依诺,王琪..肺癌新辅助治疗的争议与共识[J].中国实用内科杂志,2025,45(6):454-462,9.基金项目
国家自然科学基金(82473056,82027805) （82473056,82027805）
